

Curriculum Vitae

First and family name**Marco Dottorini****Present position**

Since 8/9/1987 1st level medical executive at the Division of General Medicine Hospital of Gubbio ,from 2000 with professional assignment of high speciality on pneumology .

Since 1/11/ 2007, at the Pulmonary Rehabilitation and Tb Prevention Service (local public health unit , Perugia), with the professional assignment of high speciality on pulmonary rehabilitation since 1/8/2011 Cief of UOS Pulmonary Rehabilitation and Tb Prevention Service

Address

(Full office address incl. postal/zip code)

AUSL UMBRIA n.1, Perugia
Via della Pallotta, 42
06126 Perugia

Telephone Area Code and number

+39755412690

Medical education

Name of school

University of Perugia

City, Country

Perugia (Italy)

Duration of education

6 years

Degree attained

M.D.

Education completed in year

6 years (Degree attained in 1980)

Postgraduate training

Type of training

Specialization in Thysiology and Respiratory Diseases

Name of institution

University of Milan

City, Country

Milan, Italy

Duration of training

3 years

Degree attained

Specialist in Thysiology and Respiratory Diseases

Training completed in year

1983

Type of training

Specialization in Clinical Allergology and Immunology

Name of institution

University of Florence

City, Country

Florence, Italy

Duration of training

4 years

Degree attained

Specialist in Clinical Allergology and Immunology

Training completed in year

1987

Fellowship to Scientific Society

AIPO (Associazione Italiana Pneumologi Ospedalieri)

ACCP (American College of Chest Physicians)

ERS (European Respiratory Society)

Publications

(number of written publications in relevant area(s) of research)

>70

Experience of clinical research
(number of clinical studies sponsored
by the pharmaceutical industry to
which the individual has contributed)

7 Study conducted with GCP:

COSMOS : A comparison of the effectiveness of treatment with Symbicort Turbohaler (budesonide / formoterol 160/4.5 mcg) single inhaler therapy and Seretide Diskus (salmeterol/fluticasone 50/100, 50/250, or 50/500) plus Ventoline (salbutamol) as needed in steroid-treated adult and adolescent asthmatic subjects. A randomized, open, parallel-group. Phase IIIB, multicentre, 12 month study"

UPLIFT "A randomized, double-blind, placebo-controlled, parallel group trial assessing the rate of decline of lung function with tiotropium 18 mcg inhalation capsule once daily in patients with chronic obstructive pulmonary disease (COPD)

CAST : Controllo dell'Asma con Symbicort Turbohaler: efficacia e tollerabilità di uno schema posologico flessibile individualizzato in confronto allo schema convenzionale con somministrazione due volte al giorno" Protocollo AIPO-SIMer,

TIOSPIR (Behringer Ingelheim) Tiotropium Safety and Performance in Respimat: randomized, prospective evaluation of the safety and efficacy of tiotropium Respimat, as compared with tiotropium HandiHaler.

OPTIMO study: withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients .AIPO Study Group

PREFER prevalenza delle comorbidità in pazienti BPCO gravi e molto gravi, con frequenti riacutizzazioni.

MISTRAL, in corso , per la valutazione della gestione farmacologica del paziente con BPCO.

Signature



Date of signature

2/7/2016